![Adam Levy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Adam Levy
Directeur Financier/CFO chez
ACRIVON THERAPEUTICS, INC.
Fortune : 137 957 $ au 31/08/2026
Profil
Adam D.
Levy is currently Director at Vesselon, Inc. and will be Chief Financial Officer at Acrivon Therapeutics, Inc. starting in 2025.
Former roles include Executive Director-Investor Relations at Gilead Sciences, Inc. from 2016 to 2020, EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc. in 2021, Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc. from 2021 to 2022, and Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. from 2022 to 2023.
Education includes an MBA from Kellogg School of Management and undergraduate studies at the University of Illinois At Urbana–Champaign.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/08/2026 | 66 008 ( 0,15% ) | 137 957 $ | 31/08/2026 |
Postes actifs de Adam Levy
| Sociétés | Poste | Début |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Directeur Financier/CFO | 01/04/2025 |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Develops a portable ultrasound device for brain stroke treatment | Directeur/Membre du Conseil | - |
Anciens postes connus de Adam Levy
| Sociétés | Poste | Fin |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Investor Relations Contact | 01/01/2023 |
| TURG POIN | Investor Relations Contact | 01/01/2022 |
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | 31/12/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2020 |
Formation de Adam Levy
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
57
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Develops a portable ultrasound device for brain stroke treatment | Health Technology |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
 Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Acrivon Therapeutics, Inc.
 Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
